Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure

Table 2 Changes in blood pressure and vascular parameter

Parameter	n	Empa baseline	Empa 12 weeks	Change	p-value	n	Placebo baseline	Placebo 12 weeks	Change	p-value
Brachial systolic BP (mmHg)	30	131.4 ± 18.2	124.1 ± 12.9	− 6.8 ± 10.9	0.005	16	130.3 ± 22.0	129.2 ± 16.6	− 1.1 ± 16.5	0.796
Brachial diastolic BP (mmHg)	30	75.4 ± 10.1	73.3 ± 9.0	− 1.9 ± 7.9	0.269	16	76.0 ± 12.6	75.3 ± 8.7	− 0.7 ± 9.5	0.877
Brachial heart rate (bpm)	30	63.1 ± 10.2	63.3 ± 13.7	− 0.5 ± 8.3	0.650	16	60.0 ± 9.3	58.1 ± 12.6	− 1.9 ± 8.0	0.201
Systolic 24 h ABP (mmHg)	33	120.8 ± 16.2	117.5 ± 12.0	− 4.3 ± 11.6	0.038	14	122.1 ± 15.1	128.3 ± 18.1	+ 4.7 ± 8.6	0.084
Diastolic 24 h ABP (mmHg)	33	72.2 ± 9.4	70.9 ± 7.6	− 2.2 ± 7.3	0.085	14	74.6 ± 10.1	77.5 ± 10.6	+ 1.3 ± 3.8	0.246
Central systolic BP (mmHg)	30	119.1 ± 15.2	112.7 ± 10.5	− 5.9 ± 9.1	0.008	16	118.2 ± 18.7	117.0 ± 14.4	− 1.2 ± 13.4	0.877
Central pulse pressure (mmHg)	30	42.7 ± 9.1	38.5 ± 7.7	− 4.0 ± 4.5	< 0.001	16	41.1 ± 9.0	40.8 ± 8.9	− 0.4 ± 8.0	0.776
Forward pulse pressure height (mmHg)	30	28.8 ± 6.3	26.2 ± 5.5	− 2.4 ± 3.8	0.001	16	27.9 ± 7.3	27.6 ± 7.6	− 0.3 ± 6.2	0.856
Resting pulse pressure height (mmHg)	30	17.8 ± 3.9	15.8 ± 3.5	− 1.9 ± 2.3	< 0.001	16	17.2 ± 3.8	16.3 ± 4.5	+ 3.7 ± 1.0	0.182

ISSN: 1475-2840